Demand Generation in a Cookieless World: Intent Signals That Work
Demand Generation in a Cookieless World: Intent Signals That Actually Work
If you've been in B2B marketing for more than a few years, you've lived through at least one version of this conversation: the tools we've relied on are changing, the old playbook is breaking down, and we need to figure out what comes next. The death of the third-party cookie is that conversation's current chapter. And while it's been a slow-moving story (Google has delayed the full removal of third-party cookies in Chrome more times than most of us can count), the direction of travel is clear. The targeting infrastructure that B2B demand generation has leaned on heavily for the past decade is eroding, and the marketers who adapt early will have a real advantage over those who wait for the change to force their hand. The good news: the alternatives aren't just adequate. In many cases, they're better.
What We're Actually Losing
To understand what to replace, it helps to be specific about what third-party cookies actually did for demand generation. They enabled cross-site tracking, following a user from your website to other websites and building a behavioral profile over time. That profile powered retargeting campaigns, lookalike audience modeling, and the kind of frequency-capped, multi-touch display advertising that kept your brand in front of prospects who had visited your site but hadn't converted. For life sciences companies with long sales cycles and diffuse buying committees, that persistence mattered. A scientist who visited your product page in January and then saw a relevant ad in March was being nudged along a journey that third-party cookies made possible. Without them, that specific mechanism breaks. But what it leaves behind is a reason to build something more durable.
First-Party Data: The Foundation You Should Have Been Building Anyway
The most important shift in cookieless demand generation is the move from renting an audience to owning one. First-party data, meaning information your prospects and customers give you directly through their interactions with your owned channels, is both more valuable and more durable than anything you could buy or borrow through third-party tracking. In practice, building first-party data for a life sciences company means creating genuine reasons for your audience to identify themselves to you. Gated content that's worth gating: original research, technical white papers, protocol guides, benchmark reports. Not the "download our brochure" variety that nobody trades their email address for anymore. Webinars and virtual events that attract real practitioners. Newsletter subscriptions that deliver actual value. Demo requests and product trials that signal high intent.
The quality of what you're offering in exchange for contact information determines the quality of the audience you build. If you're generating a list of email addresses attached to people who downloaded a generic industry overview, you have a weak asset. If you're generating a list of scientists and lab managers who consumed a detailed technical guide on automating lab workflows, you have something genuinely useful. The investment required to build that kind of first-party asset is higher. The returns are proportionally better.
Intent Signals: Reading the Room Without Cookies
Beyond first-party data, the cookieless world has accelerated the maturation of intent data as a demand generation tool, and this is where things get interesting.
Behavioral signals on your own properties are the clearest intent indicators you have. Someone who visits your product page, reads three blog posts, downloads a technical guide, and then visits your pricing page is telling you something important without saying a word. Marketing automation platforms like HubSpot, Marketo, and Pardot have always been able to track this within your environment, and this capability is unaffected by the discontinuation of cookies. If you're not using progressive lead scoring based on on-site behavior, that's a high-priority gap to close.
Third-party intent data platforms like Bombora, TechTarget Priority Engine, and G2 Buyer Intent aggregate signals from across the web: content consumption patterns, review site activity, category research. These platforms use their own first-party data, collected with consent on their own properties, to build intent signals that are not dependent on third-party cookies. For life sciences companies targeting a defined set of accounts, layering intent data onto your ABM programs can dramatically improve prioritization, letting you focus sales and marketing energy on the accounts that are actually in a buying motion right now.
Social and community signals are harder to track but increasingly important. A significant portion of B2B buying research happens in places that are essentially invisible to traditional analytics: private Slack communities, LinkedIn DMs, industry forums, and conference conversations. You can't measure this directly, but you can influence it. Active participation in relevant communities, a strong LinkedIn presence, and a reputation for producing content that practitioners share with each other all build influence in these channels. When a scientist asks their peer network "who do you use for lab automation," you want your name to come up.
Search intent data, available through tools like SEMrush, Ahrefs, and Google Search Console, tells you what your target audience is actively searching for, which is a proxy for what they're thinking about. Mapping keyword intent to your content and paid search strategy ensures you're present at the moments when intent is highest and most legible.
ABM as the Organizing Framework
In a world where broad-based retargeting is harder, Account-Based Marketing becomes a more attractive organizing framework for demand generation. Rather than casting a wide net and hoping the algorithm finds the right people, ABM starts with a defined list of target accounts and orchestrates marketing activity specifically around those accounts.
For life sciences companies, where the total addressable market is often well-defined, deal sizes are meaningful, and sales cycles are long, ABM is a natural fit regardless of the cookie situation. But the cookieless transition makes it more compelling still, because the precision of ABM reduces the dependence on the broad behavioral tracking that third-party cookies enabled.
A well-executed ABM program in this environment combines intent data to prioritize accounts, first-party content assets to attract and engage them, LinkedIn targeting to reach specific personas within those accounts, and tight sales and marketing alignment to ensure that when an account raises its hand, someone is ready to respond quickly.
It's not a simple motion to run. But for complex B2B sales in life sciences, it's the right one.
What This Means for Your Measurement Approach
One underappreciated consequence of the cookieless shift is that it breaks some of the attribution models demand generation teams have relied on. Multi-touch attribution that tracked a prospect's journey across multiple sites and sessions becomes harder to reconstruct without third-party cookies. The response isn't to abandon measurement. It's to diversify it. Alongside whatever digital attribution your tools can still support, invest in direct conversation with your customers and prospects about how they found you and what influenced their decision. Ask in sales calls. Include it in onboarding surveys. Run periodic voice-of-customer research. The qualitative signal you get from simply asking people is often more accurate than the algorithms that were never as reliable as they looked.
Pipeline contribution, account engagement scores, and revenue influence are also more durable metrics than last-click or multi-touch attribution models that depend on complete tracking data. Orient your reporting around what you can measure reliably, and be honest about the limits of what you can't.
The Underlying Point
The cookieless transition is genuinely disruptive to some of the tactics demand generation has relied on. But the fundamentals it pushes you toward, including owned audience, genuine content value, intent-based prioritization, and account focus, are better marketing practices than what they're replacing.
The brands that treat this as a trigger to build something more durable will emerge stronger. The ones waiting for a technical workaround that recreates the old model are likely to be disappointed. Build the asset. Earn the attention. Read the intent. That's the playbook.
I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.
Contact Us



